Roche Partners with Foundation Medicine for Comprehensive Genomic Profiling

Roche and Foundation Medicine, Inc. have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI’s common stock not already owned by Roche and its affiliates at a price of USD 137.00 per share in cash. This corresponds to a total transaction value of USD 2.4 billion on a fully diluted basis, and a total company value of USD 5.3 billion on a fully diluted basis. This price represents a premium of 29 percent to FMI’s closing price on June 18, 2018 and a premium of 47 percent and 68 percent to FMI’s 30-day and 90-day volume weighted average share price on June 18, 2018, respectively.

The merger agreement has been unanimously approved by the board of Roche and a special committee of the independent directors of FMI and by its full board of directors with the Roche designated directors abstaining from the deliberations and vote. All current members of the FMI board have indicated that they intend to tender their FMI shares in the tender offer. Citi is acting as financial advisors to Roche and Davis Polk & Wardwell LLP is acting as legal counsel to Roche. Goldman Sachs & Co. LLC is acting as financial advisor to the FMI Special Committee and Goodwin Procter LLP is acting as legal counsel to the FMI Special Committee.

Foundation Medicine services include a full suite of comprehensive genomic profiling (CGP) assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine and Roche share the philosophy that every cancer patient should have access to personalized care informed by validated molecular information. Joining forces with Roche as an independent operating company allows Foundation Medicine to continue its collaboration with Roche, as well as our biopharma partners, to drive ubiquitous access to CGP testing and innovative data services.

“This is important to our personalized healthcare strategy as we believe molecular insights and the broad availability of high quality comprehensive genomic profiling are key enablers for the development of, and access to, new cancer treatments.”

Daniel O’Day
Chief Executive Officer,
Roche Pharmaceuticals